Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected ...

The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

Chinese contract research and manufacturing outfit ChemPartner is building out its U.S. footprint in the heart of the ...

Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its ...

Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup right on the heels of a similar deal unveiled earlier this month. | Right on the heels of a similar ...

Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

ProVerum has raised $80 million in venture capital funding to complete the development of its minimally invasive, stent-like implant to relieve the urinary symptoms of an enlarged prostat | The Dublin ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...